The clinicopathologic basis of Graves' ophthalmopathy: A review

European Journal of Ophthalmology

Volumn 15, Issue 3, 2005, Pages 315-323

  Kloprogge, S ^a   Kowal, L ^a   Wall, J ^b   Frauman, Albert G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Associated basedow's eye; Graves' ophthalmopathy; Thyroid

Indexed keywords

BOTULINUM TOXIN; CYCLOSPORIN; IMMUNOGLOBULIN; OCTREOTIDE; STEROID;

EYE DISEASE; GRAVES DISEASE; HUMAN; IRRADIATION; ORBIT; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

EID: 21744451778     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500301     Document Type: Review

References (105)

1. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol 1995; 43: 55-68.
2. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocrine Rev 1993; 14: 747-93.
3. Coats DK, Paysse EA, Plager DA, Wallace DK. Early strabismus surgery for thyroid ophthalmopathy. Ophthalmology 1999; 106: 324-9.
4. Hales IB, Rundle FF. Ocular changes in Graves disease. Q J Med 1960; 29: 113-26.
5. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001; 108: 1523-34.
6. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000; 355: 1505-9.
7. Chavis PS. Thyroid and the eye. Curr Opin Ophthalmol 2002; 13: 352-6.
8. Major BJ, Busuttil BE, Frauman AG. Graves' ophthalmopathy: pathogenesis and clinical implications. Aust NZ J Med 1998; 28: 39-45.
9. Simonsz HJ, Kommerell G. Increased muscle tension and reduced elasticity of affected muscles in recent-onset Graves' disease caused primarily by active muscle contraction. Doc Ophthalmol 1989; 72: 215-24.
10. Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol 1993; 38: 367-72.
11. Natt N, Bahn RS. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997; 26: 129-36.
12. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 1995; 132: 532-41.
13. Paridaens DA, van Den Bosch WA, van der Loos TL, Krenning EP, van Hagen MP. The effect of etanercept on Graves' ophthalmopathy. A pilot study. Presented at Vancouver Orbital Symposium, Vancouver, Canada; 196th annual meeting of the Dutch Ophthalmic Society, Groningen, The Netherlands; 20th annual meeting of the European Society of Ophthalmic Plastic & Reconstructive Surgery, Muenster, Germany, 2002; 221.
14. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993; 16: 251-7.
15. Hansson HA, Petruson B, Skottner A. Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet 1986; 1: 218-9.
16. Barrie WE. Graves' ophthalmopathy [comment]. West J Med 1993; 158: 591-5.
17. Ohtsuka K, Hashimoto M. H-magnetic resonance spectroscopy of retrobulbar tissue in Graves ophthalmopathy. Am J Ophthalmol 1999; 128: 715-9.
18. McGregor AM. Has the target autoantigen for Graves' ophthalmopathy been found? Lancet 1998; 352: 595-6.
19. Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235-6.
20. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639-44.
21. El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 2004; 34: 482-91.
22. Salvi M, Zhang ZG, Haegert D, Woo M, Liberman A, Cadarso L, Wall JR. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metabol 1990; 70: 89-94.
23. Maugendre D, Massart C. Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol 2001; 54: 89-96.
24. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies [erratum appears in Endocrine Rev 1999; 20: 100]. Endocrine Rev 1998; 19: 673-716.
25. Nugent RA, Belkin RI, Neigel JM, et al. Graves orbitopathy: correlation of CT and clinical findings. Radiology 1990; 177: 675-82.
26. Patrinelly JR, Osborn AG, Anderson RL, Whiting AS. Computed tomography features of nonthyroid extraocular muscle enlargement. Ophthalmology 1989; 96: 1038-47.
27. Scott AB. Botulinum toxin treatment of strabismus. In Campos EC, ed. Strabismus and Ocular Motility Disorders. Proceedings of the sixth meeting of the International Strabismological Association; Surfer's Paradise, Australia, 1990; 401-6.
28. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-8.
29. Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986; 16: 415-22.
30. Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2002; 109: 2100-7.
31. Wilson WB, Prochoda M. Radiotherapy for thyroid orbitopathy. Effects on extraocular muscle balance. Arch Ophthalmol 1995; 113: 1420-5.
32. Ferris JD, Dawson EL, Plowman N, Adams GG, Fells P, Lee JP. Radiotherapy in thyroid eye disease: the effect on the field of binocular single vision. J Am Assoc Pediatr Ophthalmol Strabismus 2002; 6: 71-6.
33. Gerling J, Kommerell G, Henne K, Laubenberger J, Schulte-Monting J, Fells P. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiation Oncol Biol Physics 2003; 55: 182-9.
34. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002; 13: 280-7.
35. Feldman KA, Putterman AM, Farber MD. Surgical treatment of thyroid-related lower eyelid retraction: a modified approach. Ophthalmic Plast Reconstruct Surg 1992; 8: 278-86.
36. Mounts MP, Sasim IV. A single technique to correct various degrees of upper lid retraction in patients with Graves' orbitopathy. Br J Ophthalmol 1999; 83: 81-4.
37. Gay AJ, Wolkstein MA. Topical guanethidine therapy for endocrine lid retraction. Arch Ophthalmol 1966; 76: 364-7.
38. McNab AA. Orbital decompression for thyroid orbitopathy. Aust NZ J Ophthalmol 1997; 25: 55-61.
39. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology 1994; 101: 223-30.
40. Lee AG, McKenzie BA, Miller NR, Loury MG, Kennedy DW. Long term results of orbital decompression in thyroid eye disease. Orbit 1995; 14: 59-70.
41. Gair EJ, Lee JP, Khoo BK, Maurino V. What is the role of botulinum toxin in the treatment of dysthyroid strabismus? J Am Assoc Pediatr Ophthalmol Strabismus 1999; 3: 272-4.
42. Biglan AW. Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surgery 1994; 25: 186-8.
43. Simonsz HJ, Vingerling JR. Botulinum toxin as adjunct for refractory compressive optic neuropathy in Graves' disease. Orbit 1998; 17: 173-8.
44. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995; 42: 571-80.
45. Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997; 136: 416-22.
46. Prophet H, Matic GB, Winkler RE, et al. Two cases of refractory endocrine ophthalmopathy successfully treated with extracorporeal immunoadsorption. Ther Apher 2001; 5: 142-6.
47. Prummel MF, Wiersinga WM. Immunomodulatory treatment of Graves' ophthalmopathy. Thyroid 1998; 8: 545-8.
48. Cockerham KP, Pal C, Jani B, Wolter A, Kennerdell JS. The prevalence and implications of ocular hypertension and glaucoma in thyroid-associated orbitopathy [comment]. Ophthalmology 1997; 104: 914-7.
49. Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995; 5: 231-4.
50. Weetman AP, So AK, Warner CA, Foroni L, Fells P, Shine B. Immunogenetics of Graves' ophthalmopathy. Clin Endocrinol 1988; 28: 619-28.
51. Weetman AP, Poole J. Failure to find an association of blood group P1 with thyroid-associated ophthalmopathy. Clin Endocrinol 1992; 37: 423-5.
52. Villanueva R, Inzerillo AM, Tomer Y, et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000; 10: 791-8.
53. Frecker M, Stenszky V, Balazs C, Kozma L, Kraszits E, Farid NR. Genetic factors in Graves' ophthalmopathy. Clin Endocrinol 1986; 25: 479-85.
54. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med 1994; 96: 457-62.
55. Wiersinga WM, Smit T, van der Gaag R, Mounts M, Koornneef L. Clinical presentation of Graves' ophthalmopathy. Ophthalmic Res 1989; 21: 73-82.
56. Tanwani LK, Lohano V, Ewart R, Broadstone VL, Mokshagundam SP. Myasthenia gravis in conjunction with Graves' disease: a diagnostic challenge. Endocrinol Pract 2001; 7: 275-8.
57. Kusuhara T, Nakajima M, Imamura A. Ocular myasthenia gravis associated with euthyroid ophthalmopathy. Muscle Nerve 2003; 28: 764-6.
58. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease [comment]. JAMA 1993; 269: 479-82.
59. Karadimas P, Bouzas EA, Mastorakos G. Advice against smoking is not effective in patients with Graves' ophthalmopathy. Acta Medica Austriaca 2003; 30: 59-60.
60. Kubota S, Gunji K, Ackrell BA, et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 443-7.
61. Zhang ZG, Wall JR, Bernard NF. Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1996; 80: 236-44.
62. Ross PV, Koenig RJ, Arscott P, et al. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab 1993; 77: 433-8.
63. Gunji K, Skolnick C, Bednarczuk T, et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol 1998; 87: 276-81.
64. Khoo DH, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 1999; 9: 1175-80.
65. Kuroki T, Ruf J, Whelan L, Miller A, Wall JR. Antithyroglobulin monoclonal and autoantibodies cross-react with an orbital connective tissue membrane antigen: a possible mechanism for the association of ophthalmopathy with autoimmune thyroid disorders. Clin Exp Immunol 1985; 62: 361-70.
66. Kodama K, Sikorska H, Bayly R, Bandy-Dafoe P, Wall JR. Use of monoclonal antibodies to investigate a possible role of thyroglobulin in the pathogenesis of Graves' ophthalmopathy. J Clin Endocrinol Metab 1984; 59: 67-73.
67. Gunji K, De Bellis A, Li AW, et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1641-7.
68. De Bellis A, Bizzarre A, Conte M, et al. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy. Clin Endocrinol 2003; 59: 388-95.
69. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 2000; 52: 267-71.
70. Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves' disease. J Clin Invest 2000; 105: 803-11.
71. Elisei R, Weightman D, Kendall-Taylor P, Vassart G, Ludgate M. Muscle autoantigens in thyroid associated ophthalmopathy: the limits of molecular genetics. J Endocrinol Invest 1993; 16: 533-40.
72. Kosugi S, Sugawa H, Mori T. Epitope analysis of the thyrotropin receptor, 1997. Mol Cell Endocrinol 1997; 128: 11-8.
73. Cundiff JG, Kaithamana S, Seetharamaiah GS, Baker JR, Jr., Prabhakar BS. Studies using recombinant fragments of human TSH receptor reveal apparent diversity in the binding specificities of antibodies that block TSH binding to its receptor or stimulate thyroid hormone production. J Clin Endocrinol Metab 2001; 86: 4254-60.
74. Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue [comment]. Lancet 1993; 342: 337-8.
75. Major BJ, Cures A, Frauman AG. The full length and splice variant thyrotropin receptor is expressed exclusively in skeletal muscle of extraocular origin: a link to the pathogenesis of Graves' ophthalmopathy. Biochem Biophys Res Commun 1997; 230: 493-6.
76. Luo G, Fan JL, Seetharamaiah GS, et al. Immunization of mice with Yersinia enterocolitica leads to the induction of antithyrotropin receptor antibodies. J Immunol 1993; 151: 922-8.
77. Wang PW, Hiromatsu Y, Laryea E, Wosu L, How J, Wall JR. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy. J Clin Endocrinol Metab 1986; 63: 316-22.
78. Kazuo K, Fujikado T, Ohmi G, Hosohata J, Tano Y. Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients. Br J Ophthalmol 1997; 81: 1080-3.
79. Bahn RS. The fibroblast is the target cell in the connective tissue manifestations of Graves' disease. Int Arch Allergy Immunol 1995; 106: 213-8.
80. Mengistu M, Lukes YG, Nagy EV, et al. TSH receptor gene expression in retroocular fibroblasts. J Endocrinol Invest 1994; 17: 437-41.
81. Franklyn JA. Graves' ophthalmopathy and the TSH receptor [comment]. Lancet 1993; 342: 318-9.
82. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet 1991; 338: 25-8.
83. Paschke R, Metcalfe A, Alcalde L, Vassart G, Weetman A, Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues [comment]. J Clin Endocrinol Metab 1994; 79: 1234-8.
84. Wu SL, Yang CS, Wang HJ, Liao CL, Chang TJ, Chang TC. Demonstration of thyrotropin receptor mRNA in orbital fat and eye muscle tissues from patients with Graves' ophthalmopathy by in situ hybridization. J Endocrinol Invest 1999; 22: 289-95.
85. Bell A, Gagnon A, Grunder L, Parikh SJ, Smith TJ, Sorisky A. Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol 2000; 279: C335-40.
86. Murakami M, Kamiya Y, Morimura T, et al. Thyrotropin receptors in brown adipose tissue: thyrotropin stimulates type II iodothyronine deiodinase and uncoupling protein-1 in brown adipocytes. Endocrinology 2001; 142: 1195-201.
87. Perros P, Kendall-Taylor P. Pathogenesis of thyroid-associated ophthalmopathy. Trends Endocrinol Metab 1993; 4: 270-5.
88. Weetman AP, Cohen S, Gatter KC, Fells P, Shine B. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75: 222-7.
89. Pappa A, Calder V, Ajjan R, et al. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol 1997; 109: 362-9.
90. Perros P, Kendall-Taylor P. Biological activity of autoantibodies from patients with thyroid-associated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. Q J Med 1992; 84: 691-706.
91. Faryna M, Nauman J, Gardas A. Measurement of autoantibodies against human eye muscle plasma membranes in Graves' ophthalmopathy. Br Med J Clin Res Ed 1985; 290: 191-2.
92. Hiromatsu Y, Fukazawa H, How J, Wall JR. Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbital fibroblasts in Graves' ophthalmopathy - roles of class II MHC antigen expression and gamma-interferon action of effector and target cells. Clin Exp Immunol 1987; 70: 593-603.
93. Blumer R, Lukas JR, Aigner M, Bittner R, Baumgartner I, Mayr R. Fine structural analysis of extraocular muscle spindles of a two-year-old human infant. Invest Ophthalmol Vis Sci 1999; 40: 55-64.
94. Gorman C. Ophthalmopathy of Graves' disease. N Engl J Med 1983; 308: 453-4.
95. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Nat Acad Sci USA 2001; 98: 12062-7.
96. Wall JR, Bernard N, Boucher A, et al. Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves' hyperthyroidism and Hashimoto's thyroiditis [comment]. Clin Immunol Immunopathol 1993; 68: 1-8.
97. Busuttil BE, Frauman AG. Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J Clin Endocrinol Metab 2001; 86: 2315-9.
98. Kloprogge SJ, Kapsa R, Frauman AG. The extraocular muscle thyroid stimulating hormone receptor (TSHR) and its relevance to Graves' ophthalmopathy. Proceedings of the Endocrine Society of Australia; Adelaide, Australia, 2002; 62.
99. Aird RB. Experimental exophthalmos and associated myopathy induced by the thyrotropic extract. Arch Ophthalmopathy 1940; 24: 1167-78.
100. Smelser GK. The histology of orbital and other fat tissue deposits in animals with experimentally produced exophthalmos. Am J Pathol 1939; 15: 341-55.
101. Dobyns BM. Studies on exophthalmos produced by thyrotropic hormone II. Changes induced in various tissues and organs (including the orbit) by thyrotropic hormone and their relationship to exophthalmos. Surg Gynecol Obstetrics 1946; 82: 609-10.
102. Paulson DL. Experimental exophthalmos in guinea pigs. Proc Soc Exp Biol Med 1937; 36: 604-7.
103. Smelser GK. Water and fat content of orbital tissues of guinea pigs with experimental exophthalmos produced by extracts of the anterior pituitary gland. Am J Physiol 1943; 140: 308-15.
104. Yamada M, Li AW, West KA, Chang CH, Wall JR. Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropin receptor. Autoimmunity 2002; 35: 403-13.
105. Kroll AJ, Kuwabara T. Dysthyroid ocular myopathy. Anatomy, histology, and electron microscopy. Arch Ophthalmol 1966; 76: 244-7.